Rankings
▼
Calendar
ELVN Q4 2024 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ELVN
Enliven Therapeutics, Inc.
$2B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$27M
Net Income
-$23M
EPS (Diluted)
$-0.46
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$17M
Free Cash Flow
-$17M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$326M
Total Liabilities
$16M
Stockholders' Equity
$310M
Cash & Equivalents
$124M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$27M
-$23M
-18.3%
Net Income
-$23M
-$19M
-19.7%
← FY 2024
All Quarters
Q1 2025 →